You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

HIGHLIGHTS

CORPORATE

Kedrion Biopharma runner up at the Premio Equita for the bond issued in July 2017

The prize is awarded to the companies that made the best use of the capital markets

read more 

CORPORATE

Kedrion Biopharma joins Columbia University to celebrate 50 years of Anti-D

Since 1968, billions of babies have been saved from Hemolytic Disease of the Fetus and Newborn

read more 

CORPORATE

Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme

Goal is to improve access to replacement therapies for coagulation disorders in Europe

read more 
  1. EVENTS - 26-07-2016

    SIPPET Study was WHF 2016 World Congress highlight

    A Kedrion, Grifols and LFB supported symposium featured a lecture by Dr. Manuel Carcao

    read more 
  2. CORPORATE - 17-06-2016

    Kedrion Biopharma consolidates presence on Russian market

    Joint venture with Nacimbio of RosTECH group for a technology transfer to Kirov plant

    read more 
  3. CORPORATE - 26-05-2016

    SIPPET study results published in the “New England Journal of Medicine”

    This investigator-initiated clinical study involved 42 hemophilia treatment centers from all over the world

    read more 
  4. CORPORATE - 06-05-2016

    Kedrion Biopharma for Mother's Day

    We are committed to helping eliminate Rh disease worldwide by supporting initiatives like CURhE

    read more 

Pages

For more information please contact: pressoffice@kedrion.com